ALK B ALK-ABELLO A/S

Listen in on ALK’s Capital Markets Day on 4 June 2024

Listen in on ALK’s Capital Markets Day on 4 June 2024

ALK (ALKB:DC / OMX: ALK B / AKBLF) will host a Capital Markets Day on 4 June at 13.00-17.00.

We cordially invite investors, analysts, and other interested stakeholders to listen in on our Capital Markets Day 2024, where we will share highlights from our strategy review and elaborate on key priorities and value drivers.

During the day, members of ALK’s Leadership team will cover a number of topics including global leadership in respiratory allergy, key markets and growth drivers, R&D, and ALK’s manufacturing processes and capabilities.

The speakers are as follows:

13.00 CEO keynote

Peter Halling, President & CEO

13.30 Key Markets

Søren Niegel, EVP Commercial Operations

Jacob Glenting, SVP Global Marketing, Partner Markets & China

Flora Beiche-Scholz, SVP Region Europe

15.00 R&D

Henriette Mersebach, EVP R&D

Peter Sejer Andersen, SVP Research & Drug Discovery

15.40 Product Supply

Christian G. Houghton, EVP Product Supply

16.15 Financials

Claus Steensen Sølje, EVP and CFO

Please see the attached file for a detailed program.        

The Capital Markets Day will be webcasted live and will also be available for replay on ALK’s website: . The presentation slides will be available same place before the meeting starts.

Institutional investors are also welcome to participate in person. Please contact Per Plotnikof, if you have not signed up already.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Maiken Riise Andersen, tel.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen. Find more information at

Attachment



EN
29/05/2024

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK’s tree pollen tablet (ITULAZAX®) now recommended by NICE for use i...

ALK’s tree pollen tablet (ITULAZAX®) now recommended by NICE for use in the UK health system ALK (ALKB:DC / OMX: ALK B) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of the company’s tree pollen tablet ITULAZAX® for the treatment in adults. The recommendation allows for patients to gain access to ITULAZAX® through the National Health Service (NHS) systems in England, Wales, and Northern Ireland by making it eligible for general reimbursement. The recommendation of ITULAZAX® is another significant milestone for ALK, marking the sec...

July 21, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

EURneffy® godkendt som den første nålefri behandling af anafylaksi hos...

EURneffy® godkendt som den første nålefri behandling af anafylaksi hos voksne og børn i Storbritannien Intern viden ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at det britiske Medicines and Healthcare Products Regulatory Agency (MHRA) har godkendt EURneffy® 2 mg til behandling af anafylaksi hos voksne og børn (≥30 kg) i Storbritannien. Lanceringen i Storbritannien ventes at ske inden for de kommende måneder, så snart forhandlinger om tilskud og prisfastsættelse er afsluttet. EURneffy® (varemærket for neffy® i EU og Storbritannien) er den første godkendte adrenalinnæsespray til akut...

July 18, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

EURneffy® approved as the first needle-free anaphylaxis treatment of a...

EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved EURneffy® 2 mg in the United Kingdom (UK) for anaphylaxis treatment of adults and children (≥30 kg). The market launch in the UK is expected within the coming months once market access negotiations are completed. EURneffy® (the trade name for neffy® in the EU and the UK) constitutes the first approved adrenaline nasal spray for timely emergency treatm...

July 18, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

First market launch of the adrenaline nasal spray, EURneffy®, for trea...

First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany ALK (ALKB:DC / OMX: ALK B) today announced the first market launch of EURneffy® 2 mg (the trade name for neffy® in the EU) in Germany. The launch of this first ever adrenaline nasal spray for timely emergency treatment of anaphylaxis represents a significant milestone for adults and children (≥30 kg) experiencing potentially life-threatening allergic reactions. With an intuitive, needle-free design, EURneffy® can help more people confidently use adrenaline when it matters most, su...

June 26, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK presented comprehensive data on two new paediatric AIT tablets and...

ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025 At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took place in Glasgow, Scotland, from 13 to 16 June 2025, the Danish pharmaceutical company ALK presented extensive data on anaphylaxis and paediatric allergy. During the EAACI 2025 scientific programme, ALK sponsored two major symposia and participated at several oral sessions, presenting data on the latest innovation in anaphylaxis, children with respiratory allergy, and recent advanc...

June 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch